CDRH Forecasts New Technological Trends, More Inter-Center Collaboration
This article was originally published in The Gray Sheet
Executive Summary
FDA's Office of Science and Engineering Laboratories has revamped its research priorities and retrained staff to focus on improving both premarket and postmarket programs and regulatory science across CDRH
You may also be interested in...
Personalized Genetic Test Info Added To Warfarin Drug Labeling
FDA is updating the label for the anti-clotting drug warfarin to inform physicians and patients about the usefulness of genetic testing before beginning therapy, but the agency will wait for data from ongoing studies of the tests before adding stronger recommendations for the tests
C-Path Institute Exec Targets “Points Of Pain” In Device Development
The Critical Path Institute's new Director of Medical Devices and Imaging, Ellen Feigal, MD, is working with device firms to identify key roadblocks to product development and clear the way to regulatory approval for those products
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”